A Phase 3b/4 Randomised Trial of 3 Doses of Protein-based Covid-19 Vaccine (SpikoGen)

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 15, 2022

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions

COVID-19

Interventions

BIOLOGICAL

Advax-CpG55.2 adjuvanted recombinant spike protein

recombinant SARS-CoV-2 spike protein formulated with Advax-CpG55.2 adjuvant

Trial Locations (1)

ARASMI, Adelaide

All Listed Sponsors

collaborator

Australian Respiratory and Sleep Medicine Institute

OTHER

lead

Vaxine Pty Ltd

INDUSTRY